ASCO 2021: Presentations about whole genome sequencing
At the congress of the American Society of Clinical Oncology (ASCO) on 4-8 June 2021 researchers Kris Samsom and Luuk Schipper of the Dutch Cancer Institute (NKI) have presented their findings on whole genome sequencing.
In the poster presentation
Whole Genome Sequencing (WGS) is feasible in routine clinical care
Kris Samsom of the Dutch Cancer Institute explains the results of their research in which they conclude that WGS is feasible in routine diagnostics.
In the poster presentation
Whole Genome Sequencing (WGS) improves sarcoma diagnosis and patient care
Luuk Schipper of the Dutch Cancer Institute explains how they came to the conclusion in their research that WGS can help improve the diagnosis and the treatment of patients with sarcomas.
More information
- Paper in The Journal of Molecular Diagnostics: Clinical validation of Whole Genome Sequencing for cancer diagnostics
- Interview with Kim Monkhorst, patholoog NKI/AvL about the interim results of WIDE: Whole Genome Sequencing feasible in clinical practice
- More information about WGS and the extensive DNA test: OncoAct.nl
All news
Also read
Update on the GENAYA Project: DNA from 500 Young Cancer Patients Analyzed
Should young people with cancer receive different treatment than older patients? We suspect they do, but there’s currently not enough …
Whole Genome Sequencing feasible in clinical practice
Interim WIDE analysis gives researchers more confidence in a positive outcome. On 21 September 2020, Dr. Kim Monkhorst, who is a …
Patients can benefit from whole genome sequencing for immunotherapy
Immunotherapy is an effective treatment for many people with cancer. The number of abnormalities in the DNA of the tumor in …
Cancer is caused by DNA mutations. There are an increasing number of drugs available that act on specific errors in the DNA of an individual patient’s tumor. A drug that doesn’t fit, like a key in a lock, will not work, while the risk of side effects remains.